Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cellectis SA ( (CLLS) ) has shared an update.
Cellectis announced the presentation of new research findings at the ESGCT Annual Congress in Sevilla, Spain, from October 7-10, 2025. The company highlighted the potential of circular single-stranded DNA (CssDNA) as a non-viral template for gene therapy, demonstrating high gene insertion frequency and better engraftment in HSPCs compared to viral methods. Additionally, Cellectis presented a study on TALE base editors, showing no significant off-target effects, supporting their safe use in therapeutic applications. These advancements could enhance Cellectis’ position in the gene therapy industry and offer new opportunities for stakeholders.
The most recent analyst rating on (CLLS) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
Cellectis SA’s overall stock score is driven by positive technical momentum and encouraging earnings call sentiment, particularly regarding clinical trial progress and strategic partnerships. However, financial performance challenges and valuation uncertainties due to ongoing losses weigh on the score.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis is a clinical-stage biotechnology company that specializes in gene-editing platforms to develop cell and gene therapies. The company focuses on creating allogeneic CAR T immunotherapies for oncology, offering off-the-shelf gene-edited CAR T-cells for cancer treatment, and developing gene therapies for other therapeutic areas. Cellectis operates with in-house manufacturing capabilities and is listed on the Nasdaq Global Market and Euronext Growth.
Average Trading Volume: 180,797
Technical Sentiment Signal: Hold
Current Market Cap: $252.6M
Learn more about CLLS stock on TipRanks’ Stock Analysis page.